Dengue Fever

Collaboration to Develop Dengue Vaccine

Published in Vaccine Weekly, December 21st, 1998

OraVax, Inc., Cambridge, Massachusetts and Pasteur Merieux Connaught announced that they have entered into an agreement to develop a vaccine against dengue fever, based upon OraVax's ChimeriVax platform technology.

This technology uses the yellow fever 17D vaccine virus as a vector for genes of related viruses. OraVax will develop the vaccine through completion of the first clinical trials.

Dengue fever, a mosquito-borne disease is caused by four related viruses (dengue types 1, 2, 3, and 4), and affects over 100 million people annually. Approximately 2.5 billion people living in and over 10 million persons traveling to the tropical regions of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry